Volume 21 Issue 8
Aug.  2023
Turn off MathJax
Article Contents
GAO Dai, ZHANG Zhuoli. Concept and development of glucocorticoid application in systemic lupus erythematosus under treat-to-target strategy[J]. Chinese Journal of General Practice, 2023, 21(8): 1279-1283. doi: 10.16766/j.cnki.issn.1674-4152.003102
Citation: GAO Dai, ZHANG Zhuoli. Concept and development of glucocorticoid application in systemic lupus erythematosus under treat-to-target strategy[J]. Chinese Journal of General Practice, 2023, 21(8): 1279-1283. doi: 10.16766/j.cnki.issn.1674-4152.003102

Concept and development of glucocorticoid application in systemic lupus erythematosus under treat-to-target strategy

doi: 10.16766/j.cnki.issn.1674-4152.003102
Funds:

 2021SF34

 PAYJ-034

 2022CR53

  • Received Date: 2023-01-03
    Available Online: 2023-09-13
  • Glucocorticoids (hormones for short) act in two main ways: the genomic pathway, which is the main effective pathway for oral glucocorticoids, and the non-genomic pathway, which is activated at doses of up to 100 mg/day of prednisone. Hormones have been considered as a "double-edged sword" in the treatment of SLE: on the one hand, they exert rapid and powerful anti-inflammatory and immunosuppressive effects, while on the other hand, their long-term accumulation leads to the irreversible organ damage accrual. To date, glucocorticoids remain the most critical first-line drug in the management of SLE due to the lack of safer and more effective treatments. Recent studies have shown that the long-term accumulation of glucocorticoids doses and challenges in dose reduction have become the primary barrier for target achievement in SLE treat-to-target therapy. Current research evidence suggests that longer duration of disease stabilization, more stable disease activity status, and better maintenance therapeutic regimens are key to achieving successful glucocorticoids taper. Glucocorticoids pulse can activate non-genomic effect pathways that on the one hand induce rapid disease remission without significantly increasing side effects, and on the other hand create opportunities for lower initial doses of oral glucocorticoids and rapid dose reduction. Drugs such as hydroxychloroquine, immunosuppressants, small-molecule targeted agents, and biologics are also able to help glucocorticoids dose reduction. In addition, the development of new drugs including selective glucocorticoids receptor agonists may be able to play a greater role in the future. In conclusion, how to achieve successful glucocorticoids reduction and eventual discontinuation while maintaining stable disease control has become an increasingly important topic in SLE, and more high-quality evidence-based medical evidence is needed.

     

  • loading
  • [1]
    谢长好, 李志军. 系统性红斑狼疮的诊断与治疗[J]. 中华全科医学, 2020, 18(4): 527-528. http://www.zhqkyx.net/article/id/240c4592-9f47-4c70-a324-2bf8221505c8

    XIE C H, LI Z J. Diagnosis and treatment of systemic lupus erythematosus[J]. Chinese Journal of General Practice, 2020, 18(4): 527-528. http://www.zhqkyx.net/article/id/240c4592-9f47-4c70-a324-2bf8221505c8
    [2]
    TIAN J, ZHANG D, YAO X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study[J]. Ann Rheum Dis, 2023, 82(3): 351-356. doi: 10.1136/ard-2022-223035
    [3]
    DUARTE-GARCIA A, HOCAOGLU M, VALENZUELA-ALMADA M, et al. Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades[J]. Ann Rheum Dis, 2022. DOI: 10.1136/annrheumdis-2022-222276.
    [4]
    TSELIOS K, GLADMAN D D, TOUMA Z, et al. Monophasic disease course in systemic lupus erythematosus[J]. J Rheumatol, 2018, 45(8): 1131-1135. doi: 10.3899/jrheum.171319
    [5]
    STREHL C, EHLERS L, GABER T, et al. Glucocorticoids-all-rounders tackling the versatile players of the immune system[J]. Front Immunol, 2019, 10: 1744. doi: 10.3389/fimmu.2019.01744
    [6]
    HARDY R S, RAZA K, COOPER M S. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases[J]. Nat Rev Rheumatol, 2020, 16(3): 133-144. doi: 10.1038/s41584-020-0371-y
    [7]
    INGAWALE D K, MANDLIK S K. New insights into the novel anti-inflammatory mode of action of glucocorticoids[J]. Immunopharmacol Immunotoxicol, 2020, 42(2): 59-73. doi: 10.1080/08923973.2020.1728765
    [8]
    PORTA S, DANZA A, ARIAS SAAVEDRA M, et al. Glucocorticoids in systemic lupus erythematosus. Ten questions and some issues[J]. J Clin Med, 2020, 9(9): 2709. doi: 10.3390/jcm9092709
    [9]
    RUIZ-IRASTORZA G, BERTSIAS G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs[J]. Rheumatology (Oxford), 2020, 59 (Suppl5): v69-v81.
    [10]
    GAO H, WANG Q, YU X, et al. Molecular mechanisms of glucocorticoid resistance in systemic lupus erythematosus: a review[J]. Life Sci, 2018, 209: 383-387. doi: 10.1016/j.lfs.2018.08.038
    [11]
    STREHL C, BIJLSMA J W, DE WIT M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force[J]. Ann Rheum Dis, 2016, 75(6): 952-957. doi: 10.1136/annrheumdis-2015-208916
    [12]
    BULTINK I E M, DE VRIES F, VAN VOLLENHOVEN R F, et al. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls[J]. Rheumatology (Oxford), 2021, 60(1): 207-216. doi: 10.1093/rheumatology/keaa267
    [13]
    AKIYAMA S, HAMDEH S, MICIC D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis[J]. Annals of the Rheumatic Diseases, 2021, 80(3): 384-391. doi: 10.1136/annrheumdis-2020-218946
    [14]
    LIU X, ZHANG L, ZHANG F, et al. Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China[J]. Emerg Microbes Infect, 2021, 10(1): 2303-2312. doi: 10.1080/22221751.2021.2004864
    [15]
    ABE K, ISHIKAWA Y, KITA Y, et al. Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study[J]. Arthritis Res Ther, 2022, 24(1): 179. doi: 10.1186/s13075-022-02869-9
    [16]
    SHIMADA H, WAKIYA R, KANENISHI K, et al. Preterm birth is strongly affected by the glucocorticoid dose during pregnancy in women complicated by systemic lupus erythematosus[J]. Arthritis Res Ther, 2022, 24(1): 10. doi: 10.1186/s13075-021-02699-1
    [17]
    UGARTE-GIL M F, MAK A, LEONG J, et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies[J]. Lupus Sci Med, 2021, 8(1): e000590. DOI: 10.1136/lupus-2021-000590.
    [18]
    DAVIDSON J E, FU Q, RAO S, et al. Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort[J]. Lupus Sci Med, 2018, 5(1): e000237. DOI: 10.1136/lupus-2017-000237.
    [19]
    APOSTOLOPOULOS D, KANDANE-RATHNAYAKE R, LOUTHRENOO W, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study[J]. The Lancet Rheumatology, 2020, 2(1): e24-e30. doi: 10.1016/S2665-9913(19)30105-5
    [20]
    DANZA A, GRANA D, SOTO E, et al. Prednisone and long-term damage in systemic lupus erythematosus: Which is the threshold dose? A pilot study[J]. Lupus, 2022, 31(7): 880-884. doi: 10.1177/09612033221093485
    [21]
    LITTLE J, PARKER B, LUNT M, et al. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort[J]. Rheumatology (Oxford), 2018, 57(4): 677-687. doi: 10.1093/rheumatology/kex444
    [22]
    GAO D, HAO Y, MU L, et al. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naive patients with systemic lupus erythematosus[J]. Rheumatology (Oxford), 2020, 59(11): 3400-3407. doi: 10.1093/rheumatology/keaa120
    [23]
    PARRA SANCHEZ A R, VOSKUYL A E, VAN VOLLENHOVEN R F. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation[J]. Nat Rev Rheumatol, 2022, 18(3): 146-157. doi: 10.1038/s41584-021-00739-3
    [24]
    ZEN M, GATTO M, DORIA A. Defining the targets in SLE management: insights and unmet gaps[J]. Ann Rheum Dis, 2022, 81(11): 1483-1485. doi: 10.1136/ard-2022-222991
    [25]
    SAMOES B, ZEN M, ABELHA-ALEIXO J, et al. Ca. veats and pitfalls in defining low disease activity in systemic lupus erythematosus[J]. Autoimmun Rev, 2022, 21(10): 103165. DOI: 10.1016/j.autrev.2022.103165.
    [26]
    FRANKLYN K, LAU C S, NAVARRA S V, et al. Definition and initial validation of a lupus low disease activity state (LLDAS)[J]. Ann Rheum Dis, 2016, 75(9): 1615-1621. doi: 10.1136/annrheumdis-2015-207726
    [27]
    VAN VOLLENHOVEN R F, BERTSIAS G, DORIA A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force[J]. Lupus Sci Med, 2021, 8(1): e000538. DOI: 10.1136/lupus-2021-000538.
    [28]
    BANDHAN I H, ISLAM M N, AHMAD H I, et al. Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients[J]. Int J Rheum Dis, 2022, 25(2): 121-130. doi: 10.1111/1756-185X.14265
    [29]
    TSELIOS K, GLADMAN D D, SU J, et al. Gradual glucocorticosteroid withdrawal is safe in clinically quiescent systemic lupus erythematosus[J]. ACR Open Rheumatol, 2021, 3(8): 550-557. doi: 10.1002/acr2.11267
    [30]
    MIYAWAKI Y, SHIMIZU S, OGAWA Y, et al. Association of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study[J]. Arthritis Res Ther, 2021, 23(1): 79. doi: 10.1186/s13075-021-02466-2
    [31]
    RUIZ-IRASTORZA G. Can we effectively treat lupus and reduce the side-effects of glucocorticoids?[J]. The Lancet Rheumatology, 2020, 2(1): e3-e5. doi: 10.1016/S2665-9913(19)30132-8
    [32]
    HOUSSIAU F A. Time to change the primary outcome of lupus trials[J]. Ann Rheum Dis, 2019, 78(5): 581-582. doi: 10.1136/annrheumdis-2018-213788
    [33]
    FANOURIAKIS A, KOSTOPOULOU M, ALUNNO A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6): 736-745. doi: 10.1136/annrheumdis-2019-215089
    [34]
    FANOURIAKIS A, KOSTOPOULOU M, CHEEMA K, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis[J]. Ann Rheum Dis, 2020, 79(6): 713-723. doi: 10.1136/annrheumdis-2020-216924
    [35]
    MATHIAN A, PHA M, HAROCHE J, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial[J]. Ann Rheum Dis, 2020, 79(3): 339-346. doi: 10.1136/annrheumdis-2019-216303
    [36]
    JI L, GAO D, HAO Y, et al. Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal[J]. Rheumatology (Oxford), 2022, 62(1): 181-189. DOI: 10.1093/rheumatology/keac225.
    [37]
    TANI C, ELEFANTE E, SIGNORINI V, et al. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience[J]. RMD Open, 2019, 5(2): e000916. DOI: 10.1136/rmdopen-2019-000916.
    [38]
    GOSWAMI R P, SIT H, GHOSH P, et al. Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre[J]. Clin Rheumatol, 2019, 38(4): 1089-1097. doi: 10.1007/s10067-018-4377-7
    [39]
    FASANO S, COSCIA M A, PIERRO L, et al. Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study[J]. Lupus, 2021, 30(6): 991-997. doi: 10.1177/09612033211002269
    [40]
    OON S, HUQ M, GODFREY T, et al. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2018, 48(2): 221-239. doi: 10.1016/j.semarthrit.2018.01.001
    [41]
    MOK C C, HAMIJOYO L, KASITANON N, et al. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus[J]. The Lancet Rheumatology, 2021, 3(7): e517-e531. doi: 10.1016/S2665-9913(21)00009-6
    [42]
    FANOURIAKIS A, TZIOLOS N, BERTSIAS G, et al. Update omicronn the diagnosis and management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2021, 80(1): 14-25. doi: 10.1136/annrheumdis-2020-218272
    [43]
    RUIZ-IRASTORZA G. Prednisone in systemic lupus erythematosus: taper quickly, withdraw slowly[J]. Rheumatology (Oxford), 2021, 60(12): 5489-5490. doi: 10.1093/rheumatology/keab347
    [44]
    ZHANG T, LIANG Y, ZHANG J. Natural and synthetic compounds as dissociated agonists of glucocorticoid receptor[J]. Pharmacol Res, 2020, 156: 104802. DOI: 10.1016/j.phrs.2020.104802.
    [45]
    BUTTGEREIT F, STRAND V, LEE E B, et al. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase Ⅱb study[J]. RMD Open, 2019, 5(1): e000889. DOI: 10.1136/rmdopen-2018-000889.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (317) PDF downloads(18) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return